Resounding Success of Pherecydes Pharma's IPO on the Euronext Growth Market in Paris
Resounding Success of Pherecydes Pharma's IPO on the Euronext Growth Market in Paris Offer oversubscribed 4 times, with global demand totaling €28.1 million Capital increase of approximately €8 million, after full exercise of the Extension Clause Trading in the Company's shares begins on February 5, 2021 (FR0011651694 ALPHE) Regulatory News: Pherecydes Pharma (Paris:ALPHE) (FR0011651694 ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces the resounding success of its initial public offering on...
Source: finanznachrichten.de